Table 1.
Patients’ characteristics.
| PSC-UC [n = 32] | UC [n = 34] | Controls [n = 36] | |
|---|---|---|---|
| Blood samples, n | 31 | 33 | 34 |
| Colonic samples, n | 12 | 9 | 22 |
| Gender, males, n [%] | 20 [62] | 19 [56] | 17 [47] |
| Age, years median [range] | 52 [25–75] | 51 [22–81] | 62 [26–91] |
| Small-duct PSC, n [%] | 4 [12] | - | - |
| Liver function/biochemistry tests | |||
| ALP, median [range] IU/l | 221 [117–2947] | - | - |
| ALT, median [range] IU/l | 29.5 [13–182] | - | - |
| Bilirubin, median [range] µmol/l | 9 [5–32] | - | - |
| Hyperbilirubinaemia, n [%] > 17 µmol/l | 7 [22] | ||
| Albumin, median [range] g/l | 45 [38–49] | - | - |
| Platelets, median [range] x 109/l | 284.5 [167–607] | - | - |
| Thrombocytopenia, n [%] < 150*109/l | 0 [0] | ||
| Liver cirrhosis, n [%] | 1 [3] | ||
| IBD duration, years median [range] | 14 [3–43] | 9 [0–46] | - |
| IBD extent | |||
| Extensive, n [%] | 22 [69] | 9 [26] | - |
| Left-sided, n [%] | 3 | 18 [53] | - |
| Proctitis, n [%] | 0 [0] | 6 [18] | - |
| Previous colectomy, n [%] | 7 [22] | 1 [3] | - |
| UCEIS | |||
| 0–2, n | 8 | 7 | - |
| 3–5, n | 4 | 2 | - |
| 6–8, n | 0 | 0 | - |
| Inflammation at histology | |||
| Quiescent, n | 8 | 2 | - |
| Mild to moderate, n | 4 | 7 | - |
| Severe, n | 0 | 0 | - |
| Treatment at time of sample collection | |||
| 5-aminoslicylates, n [%] | 20 [62] | 21 [61] | - |
| Immunosuppressants, n [%] | 7 [21] | 10 [29] | - |
| Corticosteroids, n [%] | 2 [6] | 4 [11] | - |
| Anti-TNF-α | 1 [3] | 4 [11] | - |
| Anti-integrin therapy, n [%] | 0 [0] | 0 [0] | - |
| Ursodeoxycholic acid | 23 [72] | - | - |
PSC-UC, primary sclerosing cholangitis-ulcerative colitis; ALP, alkaline phosphatase; ALT, alanine transaminase; IBD, inflammatory bowel disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.